<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164355</url>
  </required_header>
  <id_info>
    <org_study_id>PT1515/19</org_study_id>
    <nct_id>NCT04164355</nct_id>
  </id_info>
  <brief_title>Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg</brief_title>
  <official_title>Evaluation of Retinal and Choriocapillary Vascular Changes Using Optical Coherence Tomography Angiography in Patients Undergoing Tadalafil 20mg on Alternative Days: a Single-centre Prospective-control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the retinal and choriocapillary vascular features in patients under the
      effects of Tadalafil 20mg using optical coherence tomography angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood
      flow to the penis thus promoting the erection.

      This drug represents an treatment for erectile dysfunction in patients after radical
      prostatectomy.

      The optical coherence tomography angiography represents a novel and non-invasive diagnostic
      technique that allows a detailed and quantitative analysis of retinal and choriocapillary
      vascular features.

      The study evaluates the changes in optical coherence tomography angiography parameters at
      baseline and after 1, 3, 6 months after the somministration of Tadalafil 20 mg orally.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The measurements of retinal and choriocapillary vessel density in patients undergoing Tadalafil after radical prostatectomy</measure>
    <time_frame>Six months</time_frame>
    <description>Changes in retinal and choriocapilary vessel density in 40 patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy, using optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillary vessel density</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Erectile Dysfunction Following Radical Prostatectomy</condition>
  <arm_group>
    <arm_group_label>Patients undergoing Tadalafil</arm_group_label>
    <description>Patients after radical prostatectomy, undergoing Tadalafil 20 mg orally, on alternative days, for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthy controls without previous surgery of radical prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 20 MG</intervention_name>
    <description>To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy</description>
    <arm_group_label>Patients undergoing Tadalafil</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participans were older than 45 years with diagnosis of erectile dysfunction due to
        surgery of radical prostatectomy. They did not receive previous treatment before Tadalafil
        and they have not other ophthalmological disease and diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age older than 45 years

          -  diagnosis of erectile dysfunction due to surgery of radical prostatectomy

          -  treatment-na√Øve with Tadalafil for erectile dysfunction

          -  absence of vitreoretinal and vascular retinal diseases

          -  absence of diabetes

        Exclusion Criteria:

          -  age younger than 45 years

          -  diagnosis of erectile dysfunction due to other causes

          -  previous treatments before Tadalafil for erectile dysfunction

          -  presence of vitreoretinal and vascular retinal diseases

          -  presence of diabetes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilda Cennamo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilda Cennamo</last_name>
    <phone>+390817463731</phone>
    <phone_ext>+390817463731</phone_ext>
    <email>da.montorio@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Montorio</last_name>
    <phone>+390817463731</phone>
    <phone_ext>+390817463731</phone_ext>
    <email>da.montorio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilda Cennamo, MD</last_name>
      <phone>00390817143731</phone>
      <email>da.montorio@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

